

GENETIC TEST REQUEST FORM HEMATO-ONCOLOGY

ORDERING PHYSICIAN	PHYSICIAN'S NAME*	DEPARTMENT		
	INSTITUTION*	PHONE		
	EMAIL*	CITY	COUNTRY	

PATIENT INFORMATION	NAME*	DATE OF BIRTH* (dd/mm/yyyy)	MEDICAL RECORD NO.	GENDER* <input type="checkbox"/> female <input type="checkbox"/> male
	<i>BILING INFORMATION (if receipt is issued on patient's behalf):</i>			
	VAT No.	ADDRESS	ZIP CODE	CITY COUNTRY

SAMPLE*	<input type="checkbox"/> PERIPHERAL BLOOD <input type="checkbox"/> BONE MARROW <input type="checkbox"/> OTHER	CLINICAL INFORMATION	1. DIAGNOSTIC HYPOTHESIS	<input type="checkbox"/> NO <input type="checkbox"/> YES
	COLLECTED AT		DATE AND TIME OF COLLECTION (dd/mm/yyyy)	2. IN THERAPEUTICS
			3. FOLLOW-UP	<input type="checkbox"/> NO <input type="checkbox"/> YES
			4. PREVIOUS TESTS	<input type="checkbox"/> NO <input type="checkbox"/> YES

REQUESTED TEST*

CYTOGENETIC TESTS (collection in lithium heparin)

Karyotype (non-stimulated cultures)
 Chromosomal breakage studies
 Karyotype (stimulated cultures)

FISH, please select rearrangement(s) to test:

<input type="checkbox"/> del(5q31)/(5q33)	<input type="checkbox"/> cMYC (8q24)	<input type="checkbox"/> t(8;14) MYC/IGH
<input type="checkbox"/> del(6q21)	<input type="checkbox"/> FGFR1 (8p11)	<input type="checkbox"/> t(8;21) RUNX1/RUNX1T1
<input type="checkbox"/> del(7q31)/-7	<input type="checkbox"/> ATM del(11q22.3)	<input type="checkbox"/> t(9;22) BCR/ABL
<input type="checkbox"/> trisomy 8	<input type="checkbox"/> KMT2A (11q23)	<input type="checkbox"/> t(11;14) IGH/CCND1
<input type="checkbox"/> trisomy 12	<input type="checkbox"/> IGH (14q32)	<input type="checkbox"/> t(11;18) API2/MALT1
<input type="checkbox"/> del(13q14.3)	<input type="checkbox"/> p53 del(17p13.1)	<input type="checkbox"/> t(12;21) ETV6/RUNX1
<input type="checkbox"/> del(13q34)	<input type="checkbox"/> RARA (17q21.2)	<input type="checkbox"/> t(14;16) IGH/MAF
<input type="checkbox"/> del(20q12)	<input type="checkbox"/> BCL2 (18q21)	<input type="checkbox"/> t(14;18) IGH/BCL2
<input type="checkbox"/> CKS1B/CDKN2C (1q21.3/1p32.3)	<input type="checkbox"/> MALT1 (18q21)	<input type="checkbox"/> t(14;18) IGH/MALT1
<input type="checkbox"/> BCL6 (3q27)	<input type="checkbox"/> ALK del(2p23);t(2;5)	<input type="checkbox"/> t(15;17) PML/RARA
<input type="checkbox"/> EGFR del(5q31)	<input type="checkbox"/> RPN1/MECOM (inv/t(3))	<input type="checkbox"/> inv(16)/t(16;16)
<input type="checkbox"/> PDGFRB (5q32)	<input type="checkbox"/> t(4;14) IGH/FGFR3	<input type="checkbox"/> t(17;22) COL1A1/PDGFB

FISH panels, please select a panel:

OncoFISH for LLC – 4 probes: 13q-, 11q-, 17p-, +12
 OncoFISH for LLC – 5 probes: 13q-, 11q-, 17p-, +12, IGH
 OncoFISH for LMA – 7 probes: t(15;17), inv(16), t(8;21), 11q-, 5q-, 7q-, BCL6
 OncoFISH for MM – 4 probes: 13q-, 17p-, t(4;14), t(11;14)
 OncoFISH for SMD – 3 probes: 5q-, 7q-, 20q-
 OncoFISH for SMD – 4 probes: 5q-, 7q-, 20q-, cen8
 FISH for large B-cell LNH – t(14;18) and t(11;14)
 FISH for diffuse large B-cell LNH – t(14;18), t(8;14) and BCL6
 FISH for MALT LNH – t(14;18) and t(11;18)

MOLECULAR DIAGNOSTIC TESTS

Qualitative tests
2 to 5 mL PB/BM in PAXgene

<input type="checkbox"/> AML-ETO; t(8;21)	<input type="checkbox"/> FLT3 (ITDs and point mutations)
<input type="checkbox"/> BCL1-IGH; t(11;14)	<input type="checkbox"/> JAK2 (exon 12)
<input type="checkbox"/> BCL2-IGH; t(14;18)	<input type="checkbox"/> JAK2 (V617F mutation)
<input type="checkbox"/> BCR-ABL; t(9;22)	<input type="checkbox"/> MLL-AF4; t(4;11)
<input type="checkbox"/> CALR (exon 9)	<input type="checkbox"/> MPL (W515L/K mutations)
<input type="checkbox"/> CBFB-MYH11; t(inv(16))	<input type="checkbox"/> NPM1
<input type="checkbox"/> CEBPA	<input type="checkbox"/> PML-RARα; t(15;17)
<input type="checkbox"/> E2A-PBX1; t(1;19)	<input type="checkbox"/> TEL-AML1; t(12;21)
<input type="checkbox"/> FIP1L1-PDGFRα; del(4)(q12)	

Quantitative tests
10 mL PB in PAXgene

<input type="checkbox"/> BCR-ABL (p210)	<input type="checkbox"/> PML-RARα
<input type="checkbox"/> TEL-AML1	<input type="checkbox"/> AML1/ETO
<input type="checkbox"/> CBFB-MYH11	

Clonal tests

<input type="checkbox"/> IGH	<input type="checkbox"/> TCRB
<input type="checkbox"/> IGK	<input type="checkbox"/> TCRD
	<input type="checkbox"/> TCRG

Other hemato-oncology tests

<input type="checkbox"/> BCR-ABL Sequencing (Imatinib resistance)	<input type="checkbox"/> c-KIT sequencing
<input type="checkbox"/> BRAF (V600 mutation)	<input type="checkbox"/> Chimerism after BMT

Requires collection of buccal cells and PB

For other genetic tests or sample requirements, please visit www.cgcgenetics.com

I certify that (i) the patient (or legal representative) has agreed to have this testing performed, by signing the patient informed consent, (ii) the patient informed consent is in agreement with the legal requirements and that (iii) I am providing CGC Genetics all relevant medical information indispensable for the testing to be performed.

I certify that (i) I was informed about the benefits, risks and limitations of the test to be performed, (ii) I put all the questions that I consider relevant and understood the answers provided. I give authorization to proceed with the requested genetic test and the use of the sample exclusively to this end.

I agree I do not agree

The sample can also be used for scientific research purposes. I agree I do not agree

PHYSICIAN'S SIGNATURE _____
(mandatory)

PATIENT'S SIGNATURE _____
(to be used in case no other informed consent is available)

Date: ____/____/____

Date: ____/____/____



CLINICAL INFORMATION

LEGAL NOTICE

Test Procedure. To perform the genetic test a biological sample is required, such as peripheral blood or bone marrow. The sample(s) should then be sent to CGC Genetics, Rua de Sá da Bandeira, 706-1, 4000-432 Porto, Portugal. After the testing is performed, CGC Genetics will send the report with the results directly to your healthcare provider.

Test Limitations. Consult with your healthcare professional to learn more about the test, including its limitations and risks, detailed description of the tested genetic changes and what the result could mean to you. Medical counselling is recommended before and after testing is performed. The following limitations may be associated with hemato-oncology genetic test: 1) The laboratory may not be able to process the test if the sample is in poor condition or due to other technical problems that prevent conclusive result. In these situations, and whenever possible, CGC Genetics will contact the patient or responsible healthcare provider to address a possible alternative. 2) There is the possibility that a second sample may be requested due to insufficient material for a proper analysis or in a situation of discrepant results.

Privacy and test results. CGC Genetics is committed to ensure patient’s data protection and confidentiality of all information originated during the whole process, according to the law. The result of your test will be directly sent to the requesting healthcare provider. Please request a copy of the test results directly to him/her. He/she is responsible for the interpretation and explanation of test results to you. CGC Genetics medical team is available to clarify your healthcare provider regarding any questions about your genetic test.

Patient rights. The patient can request the right of access, modification and cancellation of the data provided by letter addressed to CGC Genetics, Clinical Director to customercare@cgcgenetics.com.